[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.202.12. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
January 1985

Failure of Lysine?-Reply

Author Affiliations

Bldg 10, Room 12N238 Dermatology Branch National Cancer Institute National Institutes of Health Bethesda, MD 20205; University of Miami

Arch Dermatol. 1985;121(1):21. doi:10.1001/archderm.1985.01660010025003
Abstract

In Reply.—  As Dr Kagan has carefully noted, we failed to indicate the isometric form of lysine. The pure L-isomer of lysine hydrochloride was used in our study and we should have stated that in the original article.Kagan states that the lysine dosage used in our study was "low." We chose this dosage because of Kagan's study, in which this was the highest dosage administered ("312-1,200 mg of lysine daily").1 With doses of this magnitude or less, the results reported from the article were described as follows. The pain disappeared abruptly overnight in virtually every instance, new vesicles failed to appear, and resolution in the majority was considered to be more rapid than in their past experience. The most encouraging finding... was the reduction in frequency of recurrences. Taking therapeutic doses of 500-1,000 mg or increasing the maintenance dose would invariably abort recurrence.Since our dose (1,200 mg)

First Page Preview View Large
First page PDF preview
First page PDF preview
×